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ABSTRACT 
Environmental factors such as stress, anxiety and depression are important to consider with the global increase in 
chronic diseases such as cardiovascular diseases, cancer, stroke, obesity, diabetes and neurodegenerative diseases. Brain 
metabolic diseases associated with conditions such as obesity and diabetes require early intervention with diet, lifestyle 
and drug therapy to prevent diseases to various organs such as the liver with non alcoholic fatty liver disease (NAFLD) 
and other organs such as the heart, lungs thyroid, pancreas, brain, kidneys and reproductive systems. Behavioural stress 
and the molecular mechanisms that are involved in neuroendocrine diseases such as insulin resistance in obesity require 
attention since associated inflammatory processes early in the disease process have been associated with neurodegen-
erative diseases. Molecular neuroendocrine disturbances that cause appetite dysregulation and hyperphagia are closely 
linked to hyperinsulinemia, dyslipidaemia and reduced lifespan. The origins of metabolic diseases that afflict various 
organs possibly arise from hypothalamic disturbances with loss of control of peripheral endocrine hormones and neu-
ropeptides released from the brain. Diet and drug therapies that are directed to the autonomic nervous system, neuroen-
docrine and limbic systems may help regulate and integrate leptin and insulin signals involving various neuropeptides 
associated with chronic diseases such as obesity and diabetes. The understanding of brain circuits and stabilization of 
neuroanatomical structures in the brain is currently under investigation. Research that is involved in the understanding 
of diet and drugs in the stabilization of brain structures such as frontostriatal limbic circuits, hypothalamus brainstem 
circuits and parasympathetic nervous system is required. Information related to neuropeptides and neurotransmitters 
that are released from the brain and their regulation by therapeutic drugs requires further assessment. The promise of 
appropriate diets, lifestyle and drugs that target the CNS and peripheral tissues such as the adipose tissue, liver and pan-
creas may improve the prognosis of chronic diseases such as obesity and diabetes that are also closely associated with 
neurodegeneration. 
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1. Introduction 
In Western and third world countries, the global obesity 
epidemic has been reported to affect at least 10% of the 
global population [1,2]. In the United States, the pro- 
jected healthcare costs for obesity related conditions have 
been reported to be 344 billion dollars to the year 2018, 
which account for 21% of all health costs. Obesity and 
diabetes are endocrine disorders associated with hyper- 
insulinemia and other hormonal imbalance, resulting in 
inflammatory complications of various organs including 
the brain, thyroid, parathyroid, adrenal gland and pan- 
creas [3,4]. Cardiovascular disease is the major chronic 
disease and the reported increase in cases can be linked 
to the global obesity epidemic [5-8]. Stress, fatigue, anxi- 
ety and depression disorders are closely linked to other 
chronic diseases and the molecular mechanisms that are 
involved in neuroendocrine disturbances can induce or 
result from insulin resistance and lead to obesity and *Corresponding author. 
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diabetes [9-16]. Anxiety disorders include appetite dys- 
regulation, habit disoders, obsessive compulsive disor- 
ders, phobias, mood disorders and social phobias. Anxi- 
ety disorders affect mental health and induce changes in 
the brain associated with hormone dysregulation and 
biological clock alterations affecting tissues such as the 
liver and adipose tissue [17-19]. In 2013, the world health 
organization (WHO 2013) indicated that the number of 
global deaths due to chronic disease was 63% and of 
these 48% were due to cardiovascular disease, 21% to 
cancer and 12% to chronic respiratory conditions. In 
Western countries, the increase in non alcoholic fatty 
liver disease (NAFLD) and its comorbidity with other 
conditions such as rheumatoid arthritis have stimulated 
research into the molecular mechanisms in neuroendo- 
crine disorders, which may contribute to various chronic 
diseases (Figure 1). 
Consumption of excess dietary fat and calories con- 
tributes to the development of obesity with an increase in 
both size and number of fat cells. This results in an in- 
crease in lipid mediated oxidative stress, which is associ- 
ated with chronic disease [20,21]. Interest in adipose 
tissue and free fatty acid metabolism has increased as 
elevated fatty acids are known to affect the release of 
adipose tissue derived cytokines such as tumour necrosis 
factor (TNF) and interleukin 6 (IL-6), which may have 
deleterious effects on glucose and lipid metabolism; con- 
tributing to the inflammatory state of the disease [22-24]. 
Inflammation in endocrine disorders such as occurring in 
obesity and diabetes may cause increased oxidative stress 
and therefore increases thge risk for cardiovascular dis- 
ease [25-31]. Development of dietary, lifestyle and phar- 
macological strategies early in childhood may prevent 
chronic diseases involving insulin and leptin resistance 
and may delay the acceleration in the rate of chronic dis- 
eases that has become a concern in many countries includ- 
ing the United States [32-34]. The increase in childhood 
obesity is not only seen in industrialized countries but 
also in poor and developing countries [35,36]. Neuroen- 
docrine disturbances involving insulin resistance include 
thyroid dysfunction in obesity/diabetes [37-41] and this 
is closely related to lipid abnormalities seen in the meta- 
bolic syndrome characterised by raised plasma triglyc- 
eride (TG) levels and low density lipoprotein (LDL) 
cholesterol and decreased high density lipoprotein (HDL) 
cholesterol levels. The complex interactions involved in 
neuroendocrine disease induce appetite dysregulation 
that involves abnormal elevation in inflammatory media- 
tors with biochemical disorders of neuropeptides and 
hormones released from various tissues and the gastroin- 
testinal tract in these chronic diseases (Figure 2). 
Lipidomics is the large-scale study of cellular lipid 
pathways and can identify numerous individual molecu- 
lar lipids, which may assist in unravelling the molecular 
mechanisms of lipid-induced neuroendocrine regulation 
of metabolic diseases [42-52]. Appetite regulation and 
increased food intake may be influenced by individual 
lipid species via abnormal gene regulation and may pos- 
sibly involve early neurodegeneration in chronic diseases 
such as obesity and diabetes. Insulin and leptin resistance 
are key features of these conditions and are associated 
with the abnormal organ pathophysiology and disturbed 
lipid metabolism.  
2. Dyslipidemia, Insulin Resistance  
Syndrome and Obesity 
The metabolic syndrome characterized by dyslipidemia 
and hypertension is often seen in obese individuals with 
excess abdominal fat accumulation [53,54]. Lipoprotein 
sub-fractionation of plasma from obese individuals indi- 
cate the presence of large very low density lipoproteins 
(VLDL), small dense LDL and decrease in the HDL2 
subfraction of HDL. Other lipid abnormalities seen in 
obesity are increased circulating free fatty acid levels 
with excessive lipid accumulation in cells of various tis- 
sues, especially the liver with a tendency to develop non-  
 
 
Figure 1. Understanding of chronic illness to global obesity and the metabolic syndrome in western countries. 
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Figure 2. Drug therapy and diet control endocrine events with insulin resistance and brain lipid peroxidation in chronic dis- 
eases such as obesity and disabetes linked to neurodegeneration. 
 
alcoholic fatty liver disease (NAFLD). High fat and high 
glycaemic load diets provide an oversupply of lipids to 
peripheral tissues and may contribute to the development 
of insulin resistance. Lipid accumulation, particularly in 
the abdomen and around the organs in obesity may indi- 
cate high fatty acid intake, but can also be a feature of the 
co-existence of mitochondrial disease associated with 
diminished mitochondrial lipid oxidation and abnormal 
lipid metabolism.  
Previous studies have characterised lipid molecular 
species in plasma by liquid chromatography coupled to 
mass spectrometry to improve the understanding of iden- 
tification of lipids in the biology of health and disease. 
Molecular lipid species that represent sphingolipid, glyc-
erolipid, glycerophospholipid, fatty acyl, sterol, prenol 
classes have been studied [53-55]. Increases in the lipid 
fraction of lysophosphatidylcholines were found in pro- 
inflammatory and proatherogenic conditions with de- 
creases in lipids with antioxidant properties such as the 
ether phospholipids [53-55]. Insulin resistance was asso- 
ciated with triacylglycerol species containing saturated or 
monounsaturated fatty acids whereas triacylglycerol spe- 
cies containing linoleic acid (18:2 n-6) were not associ- 
ated with insulin resistance. Ceramide species were al- 
tered in obese and diabetic patients [47-51]. The plasma 
measurement allows characterization of lipid species but 
may not reflect tissue specific changes. Fatty acid analy- 
sis in NAFLD samples show numerous changes in lipid 
classes with several alterations in polyunsaturated fatty 
acids with increased metabolism of essential fatty acids 
[56]. 
To assess the effects of high fat high cholesterol 
(HFHC) diets on brain tissue lipid peroxidation, mice 
were used as a model with apo E knockin mice compared 
with control mice (Figure 3(a)) and C57BL/6J mice 
(Figure 3(b)) [57,58]. In Figure 3(a) the heat map of 
brain lipid classes is shown with increases in cholesteryl 
esters and lysophosphatidylcholine species in the brain in 
young apo E4. In aged apo E4 mice increases in choles- 
teryl esters, lysophosphatidylcholine, sphingolipid, lyso- 
phosphatidylinositol (lyso-PI) species were found. In 
C57BL/6J control mice the effects of HFHC diets were 
assessed with drug intervention using anti-oxidative acyl 
coA cholesterol acyltransferase inhibitor Avasimibe 
(Figure 3(b)). As shown in Figure 3(b) the alterations in 
brain tissue lipid peroxidation showed a marked decrease 
by the drug Avasimibe compared with brain lipids from 
HFHC treated mice where the brain lipid classes were 
markedly altered and the phosphatidylinositol (PI) was 
oxidised to the lyso-PI series. The role of HFHC diets in 
apo E4 KI mice and control mice indicate the generation 
of brain lipid mediators that are involved in the promo- 
tion of the amyloidogenic pathways of amyloid beta [59, 
60] with brain neuroinflammation and potential for neu- 
ronal death. In both control mice and apo E knockin mice, 
the HFHC diet induced NAFLD in particular apo E4 KI 
mice and control mice fatty liver was found with the role 
of insulin resistance and neuroendocrine disturbances 
closely associated with NAFLD and brain lipid peroxide- 
tion in these mice (Figures 3(a) and (b)). 
Plasma free fatty acids (FFA) might mediate the insu- 
lin resistance and impaired glucose tolerance associated 
with central obesity [42,43,52]. Dietary FFA may pro- 
mote insulin resistance by downregulation of the insulin 
signaling pathway in various tissues such as the muscle 
and liver with the promotion of TG storage in the liver 
(NAFLD) and interference with insulin action and glu- 
cose disposal. Chronically elevated plasma glucose and 
FFA results in lipotoxicity that contributes to insulin re- 
sistance and associated chronic diseases which in turn are 
connected to appetite dysregulation leading to the devel- 
opment of obesity, diabetes and neurodegenerative dis- 
eases. Alterations in brain lipid species such as phos- 
pholipids and sphingolipids in mice induced by the 
HFHC diets indicated a variety of cellular pathways for 
sphingolipids and ceramide to perturb insulin actions in  
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(a)                                                      (b) 
Figure 3. The brain lipid classes in apo E knockin mice (a) and AVASIMIBE drug treated C57BL/6J control mice (b) and 
effects of a HFHC diet. 
 
various tissues [45-48]. Ceramides and programmed cell 
death [61] have been closely linked to inflammation, 
insulin resistance and amyloidogenesis and alterations in 
lipid mediators such as sphingolipids and ceramides have 
been shown to cause defective insulin action in obesity 
and diabetes. In studies related to lipid mediators and 
neurodegeneration, plasma samples from Alzheimer’s 
disease (AD) individuals have shown to have elevated 
levels of sphingolipids and ceramides in the blood plas- 
ma with indications of insulin resistance intimately in- 
volved in the convergence of risk factors for cardiovas- 
cular disease and AD [62-64].  
3. Inflammatory Cytokines Are Linked to 
Brain Neuropeptides and  
Appetite Regulation 
The world health organization has indicated that chronic 
diseases are the major risk for death and disability and 
include obesity, diabetes, cardiovascular disease, stroke, 
cancer and neurodegenerative diseases. The role of psy- 
chological and physiological stress and high fat, high 
glycaemic load diets are important risk factors since they 
cause inflammatory processes to accelerate depressive 
illnesses that are associated with abnormal cholesterol 
metabolism and NAFLD. Chronic diseases such as obe- 
sity and diabetes are associated with elevations in proin- 
flammatory cytokines that corrupt insulin signalling with 
the promotion of the metabolic syndrome [24-27,31,65]. 
The synergistic role of stress and diets that produce adi- 
pose tissue inflammatory responses that effect neuroen- 
docrine disease have become important for interventions 
in relation to lifestyle, drug therapy and diet [65-67]. The 
reversal of early inflammatory changes induced by these 
risk factors that accompany obesity and diabetes may 
improve the prognosis of individuals and prevent the risk 
for death and disability. 
Inflammatory cytokines in chronic diseases may arise 
from the adipose tissue or from the brain and effects of 
inflammatory cytokines on the suprachiasmatic nucleus 
(SCN) in the hypothalamus may cause alteration in the 
SCN that leads to alterations in the circadian pacemaker 
that accelerate aging with the promotion of chronic dis- 
eases [65-67]. Diet and stress are sensitive to neuroendo- 
crine disease and senescence with inflammatory changes 
that promote the alterations in the hypothalamic-pituitary 
hormones and relevance to the metabolic syndrome [65- 
67]. Interest in cytokines and appetite has been clearly 
documented with the effect on food intake disorders re- 
lated to peripheral production of inflammatory cytokines 
that effect peripheral hormones such as insulin, leptin 
and gastrointestinal hormones [68].  
Interests in the understanding of cytokines to hypotha- 
lamic alterations involve various neuropeptides released 
from the brain such as corticotrophin releasing hormone 
(CRH) and neuropeptide Y (NPY) which have also been 
associated with stress, anxiety and depression [69-73]. 
Chronic diseases such as obesity and diabetes have led to 
major concerns in the Western communities and involve 
the role of abnormal release of brain CRH that is in- 
volved in appetite control and energy balance [74-78]. 
Interests in the role of leptin in the regulation of neuroin- 
flammation possibly involve the effects of neuropeptides 
on the non amyloidogenic pathways of amyloid beta in 
brain cells. HFHC diets induce brain neuroinflammation 
with lipid peroxidation (Figures 3(a) and (b)) and the 
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role of high fat diets that effect the release of leptin from 
adipose tissue is important to the control of neuroendo- 
crine disease in various chronic diseases. In obesity, 
leptin resistance is proposed to be involved in appetite 
dysregulation by poor regulation of hypothalamic NPY; 
[a stimulator of food intake], and poor regulation of CRH; 
[an inhibitor of food intake] [74,79,80]. In mice and dia-
betic rats, high fat feeding reduced hypothalamic CRH 
expression with effects on NPY [81,82]. NPY has been 
shown to play a central role in the regulation of CRH 
expression and in mental disorders such as depression 
NPY levels are decreased [70,72-74,83]. In stress and 
anxiety the effects on appetite dysregulation possibly 
involve inadequate NPY and CRH release which can 
effect liver function and cholesterol homeostasis [84-86].  
CRH has been shown to be important for protection of 
neurons and the release of CRH is associated with condi- 
tions related to stress and regulation of the non-amyloi- 
dogenic pathway by the actions of α-secretase [87-90] 
preventing the formation of inflammatory amyloid beta 
oligomers and plaque [91]. Amyloid beta oligomers in- 
duce inflammatory cytokines that have effects on various 
neuropeptides in the brain. CRH modulates the hypotha- 
lamic pituitary adrenal axis and in mouse models of AD 
chronic stressors lead to amyloid beta plaque develop- 
ment, suggesting a role for CRH in neuroendocrine dis- 
ease and neurodegeneration Activators of α-secretase that 
stimulate the non-amyloidogenic pathways of amyloid 
beta have been studied and reduced food intake and 
promotion of healthy body composition helps prevent 
inflamemation and promotes insulin sensitivity, thereby 
reducing the risk of chronic disease (Figure 4). Activa- 
tors include neuropeptides such as pituitary adenylate 
cyclase-activating polypeptide (PACAP), protein kinase 
C (PKC), statins and retinoids. [92-95]. In turn, PACAP, 
PKC activators and statins have been associated with 
reduced food intake [96-101].  
4. Neuroendocrine Diseases and Effects on 
Appetite Regulation 
The rise in chronic diseases in many countries have 
reached epidemic proportions due to diet and lifestyle, 
leading to an inability of the brain to regulate body 
weight and energy balance which can then lead to meta- 
bolic dysfunction and organ disease. In obesity and dia- 
betes the central nervous system alterations in the brain 
can lead to an increased incidence of stroke and may be 
associated with other risk factors such as hypertension 
and hypercholesterolemia. The ability of the brain to 
regulate food intake, body weight and energy balance is 
dependent on the sensing of neurons in the parabrachial 
nucleus, thalamus, lateral hypothalamus, orbitofrontal 
complex, basolateral amygdala and insular cortex and 
has become important to the origins of cardiovascular 
disease which is one of the major global diseases.  
Appetite regulation is dependent on neural activity in- 
creasing after fasting and decreasing postprandially as 
the brain senses biochemical changes in glucose, leptin 
and insulin levels in brain neurons. Studies have shown 
the effects of HFHC diets on brain lipid alterations in 
mice (Figures 3(a) and (b)) and suggest molecular 
mechanisms of endocrine disease involve lipid mediators 
and insulin resistance. Brain alterations in humans has 
been reported and induced by fat consumption with the 
extent of excess body fat in man associated with regional 
alterations in brain structure and a reduction in brain 
volume as assessed using voxel based morphometry 
(VBM) in obese individuals [102]. In these studies, body 
mass index (BMI) was negatively associated with gray 
matter (GM) density of the left post central gyrus in 
obese and lean subjects. In comparison to a group of lean 
subjects the group of obese individuals had significantly 
lower gray matter density in the post central gyrus, fron- 
tal operculum, putamen and middle frontal gyrus after  
 
 
Figure 4. Amyloidogenic and non-amyloidogenic pathways are involved in the molecular mechanisms of chronic diseases. 
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adjustment for sex, age, handedness and global tissue 
density. This study identified structural brain differences 
in human obesity in several regions of the brain that are 
involved in the regulation of taste, reward and control of 
behaviour and suggest that the increase in weight gain as 
a result of obesity may affect brain structure and function 
[103]. In obese individuals high fat diet and inflamma- 
tion of the hypothalamus has been reported and in parti- 
cular neuronal alterations in the appetite centre the arcu- 
ate nucleus have been shown [104].  
5. Lipid Mediators and Appetite Regulation 
Brain lipid heat maps in both apo E KI mice and control 
mice fed HFHC diets (Figures 3(a) and (b)) have shown 
marked alteration in phosphatidylinositol (PI) and cho- 
lesterol metabolites with relevance to effects on food 
intake and appetite dysregulation as origins of metabolic 
disease associated with the NAFLD found in these mice. 
In other studies cholesterol metabolites such as 25 hy-
droxysterol and 7 hydroxysterol have been shown to be 
associated with appetite regulation and food intake [105]. 
PI intake was shown to have anti-obese effects with 
added PI to the diet associated with appetite control [106]. 
Effects of PI oxidation closely involve the loss of control 
of appetite regulation by neuropeptides leptin and insulin 
via the PI-3 kinase pathway [107-110]. Interests in vari- 
ous lipid mediators such as ceramides in inflammation 
and chronic diseases have increased since effects on ce- 
ramides on leptin actions and on insulin resistance indi- 
cate the role of lipids in the control of the hypothalamus 
and food intake in man [111]. Further interests in lipid 
mediators that effect food intake involve the production 
of malonyl-CoA that is relevant to high fat diets where 
malonyl-CoA levels are reduced [112,113]. The enzyme 
carnitine palmitoyltransferase 1 (CPT1) isoform is ex- 
pressed in the brain and localized in neuron mitochondria 
[114]. The enzyme controls ceramide metabolism, food 
intake and energy homeostasis and effects of altered 
malonyl-CoA levels inhibit the enzyme [115-117]. The 
effects of inhibition of CPT1c by ceramide in the brain is 
related to neuropeptide dysregulation such as the orexi- 
genic effects of ghrelin mediated by neuropeptide Y 
(NPY) and agouti-related protein (AgRP) in the hypo- 
thalamic arcuate nucleus [111,115,118,119]. Malonyl- 
CoA levels are involved with leptin control of feeding 
and levels are increased in chronic diseases such as obe- 
sity and diabetes [120-122]. Lowering levels of malonyl- 
CoA is closely related to reversal of NAFLD, reduction 
in cardiovascular disease, improving insulin resistance 
and promoting the non-amyloidogenic pathways [121, 
122].  
High fat and high calorie diets provide an oversupply 
of lipids to peripheral tissues and may contribute to the 
development of insulin resistance. Lipid accumulation 
(intra adominal fat) in obesity may indicate increase fatty 
acid intake or mitochondrial disease associated with di- 
minished mitochondrial lipid oxidation and abnormal 
lipid metabolism in chronic diseases [123,124]. Interests 
in intervention with diet, lifestyle and drug therapy have 
accelerated with the increase in childhood obesity in 
Western countries. The metabolic syndrome disorder also 
shown in childhood obesity was associated with changes 
in brain volume and structure and alterations in appetite, 
hypertension and insulin resistance possibly associated 
with brain abnormalities in childhood obesity [125]. In 
obese individuals the loss of brain control is poorly un- 
derstood and alterations in brain circuitry or feeding sig- 
nals in obesity involve abnormal hormone regulation 
with poor control of appetite and body weight [12,126- 
135].  
6. Gut-Brain Interactions 
Interest in chronic diseases such as obesity has led to the 
better understanding of the communication between the 
gastrointestinal tract and the CNS that involve the hypo- 
thalamus and brain stem. These regions of the brain inte- 
grate peripheral signals such as various factors released 
from the gut and adipose tissue that have effects on neu- 
ronal activity of the hypothalamus and brain stem that 
control appetite regulation [136-141]. In response to food 
intake various gut and adipose tissue hormones have ef- 
fects on the hypothalamus, which affect central and peri- 
pheral circadian rhythms that release various neuropep- 
tides that effect appetite, energy balance and body weight 
[141-146]. Signals from the gastrointestinal tract involv- 
ed in appetite control communicate the need for food 
intake to the brain. There are chemical messengers from 
the upper GI tract e.g., cholecystokinin (CCK), secretin 
and glucose-dependent insulinotropic peptide or gastric 
inhibitory polypeptide, lower intestine glucagon-like 
peptide-1, from adipose tissue (leptin, adiponectin) and 
from the pancreas (insulin). These all communicate with 
the hypothalamus and allow food intake (orexic) or fast 
(anorexic). For example, ghrelin released from the intes- 
tine enters the brain and increases our appetite (is orexi- 
genic), while insulin and leptin do the opposite, having 
an anorexigenic signal. The hypothalamus is the proc- 
essing centre of the appetite regulating centre and inte- 
grates signals from the peripheral circulation, gastrointes- 
tinal tract and the brain. Hypothalamus neuronal cirucuits 
are involved in regulation of appetite, energy expenditure 
and control of major organ functions such as endocrine, 
gastrointestinal (GI), cardiovascular and reproductive 
systems. Neuropeptides and hormones produced by the 
hypothalamus and intestine stimulate appetite during 
fasting or inhibit appetite after feeding.  
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7. Hypothalamus and Neurodegenerative 
Diseases 
The hypothalamus is involved with many biological 
functions including appetite and body weight control, 
feeding, emotion, memory, thermoregulation, fluid bal- 
ance and insulin regulation. The three major systems that 
are involved with these functions include the autonomic 
nervous system, the neuroendocrine system and the lim- 
bic system. The hypothalamic nuclei that are involved in 
food intake include the arcuate nucleus (ARC), the 
paraventricular nucleus (PVN), the lateral hypothalamic 
area (LHA), the ventromedial nucleus and dorsomedial 
nucleus. ARC neurons at the bottom of the hypothalamus 
near the third ventricle have direct contact with periph- 
eral satiety factors like leptin and insulin. Neurons in the 
hypothalamus are responsible for various connections to 
other brain regions and one of the important functions of 
the hypothalamus is control of the daily light dark cycle. 
The suprachiasmatic nucleus (SCN) that coordinates the 
neuronal and humoural systems and the circadian 
rhythms, activates the arcuate nucleus that releases neu- 
ropeptide Y (NPY) and agouti related protein (AgRP) 
that control physiological functions (body temperature, 
melatonin release, glucocorticoid secretion and behav- 
ioural functions (feeding and memory). 
The SCN releases a number of hormones such as the 
corticosteroids and the SCN projects to the dorsal par- 
vicellular paraventricular nucleus which projects to sym- 
pathetic preganglionic neurons which regulate melatonin 
output from the pineal gland. The dorsomedial nucleus 
connects to the ventrolateral preoptic nucleus (the sleep 
promoting region) and to the orexin neurons and mela- 
nin-concentrating hormone (MCH) neurons which regu- 
late sleep and wakefulness. Appetite regulating hormones 
such as ghrelin, leptin and insulin can influence areas of 
the brain and are involved with resetting the circadian 
rhythms generated by the SCN. In response to the daily 
sleep/wake cycle corticosterone secretion increases dur- 
ing the night and related to food intake in rats with the 
release of melatonin from the pineal gland. The SCN 
may regulate the sleep-wake cycle and has effects on 
anxiety, stress and depression and food restriction effect 
the SCN and peripheral oscillators. In neuroendocrine 
diseases such as obesity, diabetes and neurodegenerative 
diseases the origins of these diseases involve the hypo- 
thalamus and SCN with alteration in appetite control in 
these individuals which is influenced by HFHC as con- 
sumed in Western countries.  
Hypothalamic neurons have been clearly shown to be 
abnormal in chronic neuroendocrine diseases that involve 
obesity and diabetes [104,147]. In AD individuals many 
brain functions are lost as the disease destroys neurons 
and the hypothalamus has been shown to be involved 
with the early stages of the disease [147-152]. The dis- 
ease advances to other regions of the brain and the pro- 
gression of the disease leads to death of the AD individ- 
ual; a period of time which varies from 10 years to 30 
years after the onset of the disease. In Parkinson’s dis- 
ease (PD) the examination of the hypothalamus have 
indicated abnormalities [151,152] with lewy body forma- 
tion and marked nerve cell degeneration. Hypothalamic 
disorders in PD assist in the interpretation of the auto- 
nomic and endocrine abnormalities in these PD individu- 
als. The abnormal crosstalk between the periphery and 
the hypothalamus involved with obesity, diabetes and 
cardiovascular disease are now closely linked to neu- 
rodegenerative diseases such as PD and AD. 
8. Diets, Peripheral Endocrine Hormones 
and Brain Neuropeptides in  
Chronic Diseases 
Future therapies that involve control of chronic diseases 
will involve diet, body size, adiposity and the role of the 
hypothalamus in the regulation of various neuropeptides 
involved in appetite regulation (Figure 5). Appetite dis- 
orders in chronic diseases are associated with abnormal 
inflammatory process, increased food intake, leptin re- 
sistance, hyperinsulinemia, neuropeptide dysregulation 
and GI hormone dysregulation. HFHC diets are closely 
linked to NAFLD and effect peripheral endocrine or cen- 
tral nervous systems that induce appetite dysregulation, 
obesity and NAFLD [153]. Influence on appetite level 
and feeding are related to neurons in the hypothalamus 
that express neuropeptides (Figure 5) that communicate 
with peripheral signals such as nutrients (glucose, amino 
acids, fatty acids) and gastrointestinal peptide hormones 
such as cholecystokinin and ghrelin. 
8.1. Adipose Tissue Hormones 
8.1.1. Leptin  
Leptin is a 16 kda protein identified in 1994 and is syn- 
thesized by fat cells and acts as a satiety factor at the 
hypothalamus. The gene encoding leptin was identified 
by positional cloning as the ob mutation and ob/ob mice 
inherit the mutation on chromosome 6 as an autosomal 
recessive condition. Elevated leptin levels are associated 
with increased adipose tissue mass and leptin levels are 
proportional to the size of adipose tissue (Reviewed 
[33,154-161]. Food intake in obese mice (ob/ob) is not 
regulated and the mice become grossly obese, hyperinsu- 
linemic and overweight. In db/db homozygous mice obe- 
sity is inherited as an autosomal recessive mutation and 
the db gene encodes the receptor for the ob gene product 
leptin. The effects of leptin on food intake and body 
weight regulation are mediated through the leptin recep- 
tor (ob-R) in the hypothalamus and binding to the ob-R  
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Figure 5. Appetite dysregulation with effects on inflammatoty cytolines, neuropeptides, adipokines, thyroid and GI hor- 
mones. 
 
involves activation of PI 3K and other lipid intermediates. 
The arcuate nucleus (ARC) of the hypothalamus that 
contains the ob-R acts as the leptin signalling centre and 
the ARC acts via the orexigenic (appetite stimulating) 
pathway mediated by neuropeptide Y (NPY) and agouti 
related protein (AgRP) the anorexigenic (appetite-sup- 
pressing) via proopiomelanocortin (POMC) pathway.  
kinase (AMPK) which phosphorylates acetylCoA car- 
boxylase indicating adiponectin regulates lipid metabo- 
lism by controlling metabolism of malonylCoA in tissues 
[173]; the metabolism of which is closely involved in 
food intake and energy expenditure in the hypothalamus 
[174-176]. Recent interests in inflammation, insulin re- 
sistance, dementia and AD implicate adiponectin as the 
adipokine involved in amyloidosis [177,178]. 
8.1.2. Adiponectin 
In chronic disease adiponectin levels are low as reviewed 
[162]. Adiponectin levels are high in plasma but are re- 
duced in obese individuals with glucose intolerance, 
dyslipidemia and high risk of atherosclerosis. Interests in 
adiponectin and its interactions with insulin and leptin in 
the hypothalamus indicate its role in food intake and 
body energy homeostasis and injections with adiponectin 
reversed insulin resistance in obese mice [163]. Adi- 
ponectin is a collagen like protein secreted by adipocytes 
and has an important role in insulin sensitivity, energy 
homeostasis, glucose and fatty acid metabolism [164- 
169]. Adiponectin has effects on peripheral tissues and 
the central nervous system with effects on the centre of 
the hypothalamus that controls hunger and satiety. Adi- 
ponectin receptors (Adip-R1 and Adip-R2) are under 
circadian rhythm and are abundantly expressed in the 
appetite centres of the hypothalamus and the POMC and 
NPY neurons of the arcuate nucleus indicating a role for 
central regulation of energy intake or expenditure [170- 
172]. Adiponectin acts via phosphorylated AMP protein  
8.2. Neuropeptides and Appetite Regulation 
Appetite regulating neuropeptides are involved in abnor- 
mal responses in brain-endocrine interactions in various 
chronic diseases and involve insulin resistance and neu- 
ropeptides such as melanocortin, NPY, melanin concen- 
trating hormone (MCH), orexins (OR), endocannabinoids 
and brain derived neurotrophic factor (BDNF). In re- 
sponse to food, neuropeptides are released from the hy- 
pothalamus which effects energy expenditure and food 
intake; essential for control of body weight regulation 
which is abnormal in neuroendocrine diseases such as 
obesity, diabetes, Parkinson’s disease and Alzheimer’s 
disease [179-182]. 
8.2.1. Neuropeptide Y 
High fat diets affect NPY [183-185] with effects in the 
brain that include effects on emotions such as stress, 
anxiety and depression [186-188]. The major physio- 
logical effects of NPY are to regulate food intake, sup- 
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press inflammation and regulate cholesterol metabolism 
[189-193]. NPY has neuroprotective effects and is pre- 
sent in the hypothalamus (orexigenic effects), hippo- 
campus, amygdala (anxioloytic effects) and nucleus ac- 
cumbens [193,194]. NPY synthesized in neurons such as 
the GABAergic neurons and transported to the synaptic 
nerve terminal where neurotransmitter modulation by 
NPY is at the pre and post synaptic terminals with the 
release of dopamine and glutamate. NPY acts with neu- 
rogenic and physiological effects at four G coupled re- 
ceptors Y1-Y5 and Y6 with targeted brain specific re- 
ceptor expression patterns [195].  
8.2.2. Melanin Concentration Hormone 
Melanin concentrating hormone (MCH) is a cyclic 19 
amino acid peptide and is mainly expressed and synthe- 
sized in the lateral hypothalamus and zona incerta [196]. 
The neuropeptide binds to the melanin concentrating 
hormone 1 receptor (MCH1R) and obese (ob/ob) mice 
have overexpression of the MCH neuropeptide in the 
hypothalamus [196,197]. The MCH levels increase upon 
fasting and MCH is important in the regulation of various 
metabolic responses after consumption of diets rich in fat 
[198,199]. MCH1R is widely expressed in the brain with 
various physiological functions such as regulation of 
energy expenditure, food intake and body weight [200, 
201]. Metabolic studies indicate that the hypothalamic 
MCH system is important in the regulation of energy 
homeostasis after consumption of high fat diets [202, 
203]. Interests in MCH1R receptor and obesity have in- 
creased with the development of MCH1R antagonists 
that are involved in regulation of MCH regulation of 
metabolic processes [204,205].  
8.2.3. Orexins 
The orexins referred to as Orexin A and Orexin B re- 
cently isolated from the hypothalamus are derived from a 
130 amino acid prepro-orexin. The orexins are synthe- 
sized in the lateral hypothalamus and preinforfornical 
area and the orexins bind to G protein coupled receptors 
referred to as Orexin receptor type 1 (OX1R) and Orexin 
receptor type 2 (OX2R). Binding of Orexins to receptors 
[206] allow neuronal firing with increased firing with 
increased intracellular calcium levels. Orexins have im- 
portant roles in mediating spontaneous physical activity 
(SPA) and non exercise induced thermogenesis (NEAT). 
Orexins activate OX2R receptors in the ARC that stimu- 
lates Na+/Ca2+ exchange in GABAergic neurons associ- 
ated with cell depolarization and these mechanisms 
stimulate feeding and appetite [207]. This may be im- 
portant in obesity therapy with control of SPA and 
NEAT important to obesity resistance [207]. Diets rich in 
fat alter hypothalamic orexin release with effects on SPA 
and NEAT and may be relevant to the pathogenesis of 
obesity [202]. 
8.2.4. Endocannabinoids 
Endocannabinoids such as endocannabinoids ananda- 
mide, 2-arachidonyl glycerol and 2-arachidonyl glyceryl 
ether have been detected in various mammals and pro- 
duced by cleavage of membrane lipid precursors (Re- 
viewed [208]. They act through G protein coupled re- 
ceptors including CB1 which is found in the nervous 
system such as the hypothalamus, peripheral nervous 
system and peripheral organs [208]. The endocannabi- 
noids are involved in the generation of ceramides and 
with the PI-3 kinase pathway involved in the control of 
neuronal survival by protection of ceramide induced 
apoptosis [209,210]. The endocannabinoids are involved 
in various physiological processes and include appetite 
regulation, emotional responses, learning and memory 
process, nociceptive transmission and motor activity. 
Leptin regulates endocannabinoids that act on the CB1 
receptor, which modulates food intake and regulation of 
energy balance [211]. Interests in the actions of endo- 
cannabinoids has increased since drugs that are antago- 
nists of CB1 receptors effect the expression of adiponec- 
tin and provide useful treatment for NAFLD in obesity 
and Type 2 diabetes [212-214]. 
8.2.5. Brain Derived Neurotrophic Factor 
Brain derived neurotrophic factor (BDNF) is synthesized 
as a 32 kda precursor as pro BDNF from the BDNF gene 
at a locus at 11q13 that contains 11 exons and can be 
processed as a 14 kda or 28 kda protein intracellularly by 
furin/proconvertases or extracellularly by plasmin or 
metalloproteinase. The mature BDNF can be transported 
into vesicles from the golgi apparatus to the cell mem- 
brane and then secreted into the extracellular space. 
BDNF is involved in the regulation of food intake and 
the levels of BDNF are controlled by high fat diets [215, 
216]. In mature neurons the BDNF peptide is involved 
with the regulation of synaptic plasticity and neurotrans- 
mission in the peripheral and central nervous system 
[215,216]. BDNF is involved in regulation of CB1 re- 
ceptor expression and the proliferation, survival and 
maintenance of neurons [217]. In obese individuals with 
the metabolic syndrome, adiponectin levels are low and 
related to low BDNF levels [210,218-220] which is also 
a feature of neurodegeneration and Alzheimer’s disease. 
8.3. Gastrointestinal Hormones and Effects on 
Hypothalamic Appetite Regulation 
After a meal gut hormones are released into the blood 
that signals to the brain to inhibit food intake and control 
energy intake. The effects of these various hormones are 
short term with the short half-life of the hormones link- 
ing communication pathways to the brain. Ghrelin is 
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characterized as an appetite stimulating hormone and 
levels rise after fasting indicating the onset of hunger and 
decrease postprandially after consumption of a meal 
(Reviewed [221,222]. It is secreted by the stomach as 
ghrelin and de-acylated (lack serine 3 acylation) with the 
acylated form essential for the activation of ghrelin re- 
ceptor (GHS-R1a). Ghrelin effect on appetite control was 
related to hypothalamic NPY/AgRP neurones which ex- 
press the ghrelin receptors [221,222]. Research in ghrelin 
based antiobesity studies have indicated a role of ghrelin 
in antiobesity therapy to date and possibilities remain for 
future research that targets other hormones for signals 
from the gut to the brain [223]. 
8.4. Miscellaneous Hormones and Peptides 
Cholecystokinin (CCK) is an intestinal hormone and has 
clear effects on appetite and energy intake and after a 
meal CCK levels rise to inhibit food intake [224,225]. In 
response to ingested calories products of proglucagon 
cleavage such as glucagon like peptide (GLP-1) increases 
in the blood plasma as they are released from the L cells 
of the gastrointestinal tract. The increase in GLP-1 is 
associated with an improvement in body weight and the 
GLP-1 receptor is found in the CNS and GLP-1 has been 
used as a therapy for obesity [226-228]. Pancreatic islet 
beta cells release insulin and along with insulin release 
another peptide referred to as amylin. Amylin binds to a 
receptor complex that contains the calcitonin receptor. 
Anorectic effects of amylin include reduced gastric emp- 
tying and food intake. Analogues of amylin have been 
used in obese and diabetic man with modest weight re- 
duction. 
Other proglucagon cleavage peptides include oxynto- 
modulin (OXM) and peptide YY (PYY) that are secreted 
with GLP-1 in response to high calorie foods. OXM re- 
duces energy intake and in obese individuals reduces 
body weight [229,230]. OXM acts via the GLP-1 recep- 
tor and has effects on the central nervous system with 
regulation of food intake. In several species PYY inhibits 
food intake and reduces body weight and administration 
of PYY to obese individuals is underway in various 
clinical trials [231,232]. Pancreatic polypeptide (PP) is 
secreted from the pancreatic islets and is similar in 
structure to PYY with reduction in food intake after ad- 
ministration to rodents and humans [233,234]. PP has 
effects on gastric ghrelin and gene expression of hypo- 
thalamic peptides such as NPY and AGRP that control 
food intake. Bombesin like peptides are found in the 
CNS and bind with high affinity to G protein coupled 
receptors with effects on hyperphagia and energy balance 
[235]. G coupled protein receptor Gpr17 is regulated by 
nutritional status and controls food intake by interaction 
with the AgRP neurons in the brain. 
8.5. Thyroid Hormones and Food Intake 
Hypothalamic control of appetite regulation and energy 
expenditure not only involves the hypothalamus but also 
the hypothalamic pituitary axis (HPT). Recent evidence 
indicates that the HPT axis can control food intake and 
effects on appetite and body weight is mediated by thy- 
roid hormones [236]. Thyroid hormones may act directly 
on the hypothalamic appetite circuits and signalling fac- 
tors such as thyroid stimulating hormone, triiodothyron- 
ine (T3) and thyroxine (T4) have recently shown to di- 
rectly influence food intake and reverse NAFLD. Impli- 
cations for thyroid hormone therapeutics to control neu- 
rodegeneration [237,238] with appetite dysregulation in 
obesity and other chronic diseases that involve thyroid 
hormones may also provide pharmacological treatments 
(Figure 5) for stress, anxiety and depression. 
9. Zinc Deficiency and Neuroendocrine  
Effects on Appetite Regulation 
Zinc deficiency has marked effects on brain zinc homeo- 
stasis and its deficiency has been associated with altera- 
tions in behaviour, learning and mental function [239- 
241]. Under stress, anxiety and in depression disorders 
zinc levels alter with marked effects on chronic illness in 
Western countries [242]. Obesity and micronutrient defi- 
ciencies are related to metabolic defects in leptin and 
insulin metabolism [243,244]. In particular obese indi- 
viduals in many studies have zinc deficiency which pre- 
disposes these individuals to glucose intolerance and 
appetite dysregulation [244-246]. Stress has been linked 
to body weight regulation and evidence suggests zinc’s 
involvement in inflammatory cytokine regulation as the 
molecular mechanism for brain dysfunction in chronic 
diseases [247].  
Interests in the neuroendocrine system, energy me- 
tabolism and peripheral cholesterol metabolism have 
increased with the strong genetic identification and in- 
volvement NPY in plasma cholesterol regulation [190, 
191]. The CNS and its control of lipid metabolism has 
identified hypothalamic NPY with evidence that NPY 
has effects on Y1 receptors to promote hepatic lipopro- 
tein secretion to promote VLDL secretion via the sym- 
pathetic nervous system and on Y2 receptors to promote 
feeding [84]. BDNF has been shown to modulate NPY 
levels in the brain and several studies have indicated the 
involvement in neuronal plasticity, behaviour, appetite 
control and body weight regulation. Zinc is involved in 
the expression of brain BDNF and NPY synthesis and its 
effects on insulin, leptin and adiponectin [248-253] in the 
periphery indicates its role in the close relationship be- 
tween appetite control and cholesterol homeostasis (Fig- 
ure 6). In zinc deficiency, NPY is unable to bind to its 
receptors to initiate an orexigenic response. 
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Figure 6. Zn deficiency in chronic diseases is associated with inflammation, appetite dysregulation andneuroendocrine dis- 
ease. 
 
In HFHC fed mice zinc deficiency was found and the 
effects on NPY dysregulation is possibly involved with 
the control of behaviour and stress responses in these 
mice as structures of the brain such as the amygdala and 
hippocampus are involved. Diets are rich in fat effect 
genes in the hypothalamus and are associated with 
plasma zinc dyshomeostasis and inflammation. The close 
relationship between zinc and lipid metabolism has been 
shown and zinc’s involvements with hundreds of en- 
zymes includes effects on fatty acid metabolism that be- 
come abnormal in individuals with insulin resistance and 
chronic diseases. In HFHC diet-fed mice, zinc deficiency 
and ill effects on thyroid hormone metabolism possibly 
are closely involved in hypercholesterolemia and NAFLD.  
10. Chronic Diseases and Overnutrition in 
Neurodegeneration  
Overnutrition in chronic disease is in involved with cen- 
tral nervous system dysregulation of neuropeptides, pe- 
ripheral hormone signalling from the pancreas (insulin), 
adipose tissue (leptin and adiponectin) and gastrointesti- 
nal tract. Excess free fatty acids inhibit insulin signalling 
and are involved in glucose dysregulation in the meta- 
bolic syndrome. Nuclear receptors include the sirtuin 
family and are NAD(+) dependent class III histone dea- 
cetylase (HDAC) proteins that target transcription factors 
to adapt gene expression to metabolic activity, insulin 
resistance and inflammation in chronic dieases has re- 
cently been reviewed [254-259]. Nutritional regulation 
by sirtuin 1 (Sirt1) that is involved with the hypothalamic 
control of food intake with regulation of the central 
melanocortin system via the fork head transcription fac- 
tor has been reported [260-263]. Nutrients such as glu- 
cose, fatty acids, zinc and amino acids regulate hypotha- 
lamic Sirt1 involved with food intake regulation, insulin 
resistance, circadian clocks, lipid metabolism and energy 
expenditure (Figure 7). Regulation of neuronal Sirt1 by 
calorie restriction is involved with endocrine and soma- 
totrophic disturbances that implicate growth hormone in 
insulin resistance and peripheral endocrine disease [264, 
265]. Furthermore Sirt1 is downregulated in chronic ob- 
structive pulmonary and kidney diseases associated with 
the metabolic syndrome and cardiovascular disease [266- 
268]. The role of Sirt1 in cardiac function involves the 
peroxisome proliferator-activated receptor-α (PPAR α)- 
Sirt1 complex and downregulation of the complex is 
closely related to inflammation related cardiovascular 
disease [269,270]. Interests in PPAR α as a major regu- 
lator of cardiac lipid metabolism also involve the tran- 
scriptional control of malonyl-CoA decarboxylase [271]. 
Cellular SIRT1 expression/activity is important in the 
promotion of the non-amyloidogenic α-secretase proc- 
essing of amyloid precursor protein which generates the 
AD peptide amyloid beta. The over-expression of SIRT1 
in the hippocampus has been shown to provide protection 
against neurodegeneration in a mouse model of AD, and 
the over-expression of SIRT1 in the brains of AD-model 
transgenic mice has been shown to reduce brain Abeta 
production and amyloid deposition. The link between 
nutrition, food intake and amyloid beta production indi- 
cates that neuroendocrine disturbances in diabetes also 
possibly involve neurodegenerative diseases such as AD 
and PD. 
11. Interventions with Drugs, Diet and  
Exercise to Prevent Chronic Diseases 
Such as Obesity and Diabetes  
The global increase in chronic diseases such as obesity 
and diabetes has led to research in the understanding of 
the use of drugs in the stabilization of brain structures 
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Figure 7. Diet and brain disease controls peripheral metabolism of glucose, lipids and proteins. 
 
ch as frontostriatal limbic circuits, hypothalamus brain- 
nti- 
ob
12. Conclusion 
nd thyroid dysfunction has be- 
su
stem circuits and parasympathetic nervous system. Inter- 
ventions in chronic diseases that reverse early neuroen- 
docrine disease are required in relation to neuropeptides 
and neurotransmitters that are regulated by these drugs 
and require further assessment. The promise of various 
drugs that target the CNS and peripheral tissues such as 
the adipose tissue, liver and muscle has indicated prom- 
ise in the past 100 years however withdrawal of these 
drugs recently has resulted in the avoidance of harmful 
side effects to various individuals with neuroendocrine 
disease such as in obesity and diabetes. Interventions 
with anti-obese drugs that improve insulin resistance, 
dyslipidemia and the metabolic syndrome have not been 
appropriate to altered lifestyles and diet conditions.  
Long term treatment of obesity with the use of a
ese drugs particularly agents that target the central ner- 
vous system have not been achieved due to safety con- 
cerns [272-274]. Anti-obesity drug discovery programmes 
have been ineffective with false starts, failures in clinical 
development, and withdrawals of drugs from the market 
and no improvement in NAFLD has been observed in 
these trials [275-278]. The discovery of novel CNS com- 
pounds that are under clinical development allow for 
assessment of agents that allow for appetite control, 
weight reduction and a reduction in the serious medical 
complications of obesity. In Western countries the ageing 
populations are afflicted with chronic diseases which are 
closely related to appetite dysregulation, zinc deficiency 
and endocrine abnormalities that are involved in the CNS 
and peripheral organ destruction. Exercise, drugs, diet 
and hormones that control calorie restriction activate 
nuclear sirtuins [279], prevent the metabolic syndromes 
and allow maintenance of the neuroendocrine system 
with reversal of NAFLD in these aged populations. 
the rate of chronic diseases that in- The acceleration in 
volve insulin resistance a
come of global concern in various countries including the 
United States. The rate of the most prevalent chronic 
disease; cardiovascular disease is linked to the metabolic 
syndrome and NAFLD and environmental factors such as 
stress, anxiety and depression are important contributors 
to the increasing rates of obesity related chronic diseases, 
such as diabetes and neurodegeneration. Intervention 
with drug therapy for obesity to prevent appetite dys- 
regulation and neuroendocrine disturbances has not been 
successful. Hyperinsulinemia and hypercholesterolemia 
are connected to abnormal SCN rhythms and hypotha- 
lamic disturbances with loss of interactions between lipid 
mediators, endocrine hormones and neuropeptides releas- 
ed from the brain. Dietary and pharmacological therapies 
that are directed to reduce amyloidogenic pathways and 
accelerated aging and also connected to food intake will 
delay the onset of inflammation, mitochondrial disease 
and neurodegeneration that are involved in the patho- 
genesis of chronic diseases. Factors that reduce behav- 
ioural stress or depression and reduce the consumption of 
HFHC diets may delay the onset of neuroendocrine dis- 
turbances that are linked to abnormal gut-brain interac- 
tions and chronic diseases in Western countries. Insulin 
resistance and the development of chronic diseases may 
be related to deficiency in essential micronutrients in 
particular PI and zinc that are connected to diet and food 
intake. Nutritional programmes that improve lifespan 
require appropriate low fat/low glycaemic load diets and 
those that promote optimal function of the endocrine 
system, which may include thyroid hormone replacement 
therapy, to maintain mental health without the disorders 
of stress, anxiety and depression that are connected to 
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biochemical changes such as insulin resistance and the 
metabolic syndrome in several chronic diseases. 
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